Division of Alphaeon Corp.
Latest From Evolus Inc.
Evolus believes its focus on the beauty business will be a differentiator for its neurotoxin Jeuveau. The company will publish head-to-head results against Botox alongside the Spring 2019 launch and does not expect a new trade secrets complaint from Botox maker Allergan to delay its product.
US FDA issued at least seven rejections to novel products; opioid analgesic sponsors had very little success, while biosimilar developers had a so-so year.
Taking into consideration global and domestic trends, South Korean pharmas are increasingly finding their own strategies to seek open innovation and collaborations to develop novel new drugs. Two leading firms from the country shared their know-how and showcased successful open innovation cases during a recent gathering organized by a national industry association.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Alphaeon Corp.
- Senior Management
David Moatazedi, Pres. & CEO
Lauren Silvernail, CFO & EVP, Corp. Dev.
J. Christopher Marmo, PhD, COO
Rui Avelar, MD, Head, R&D & CMO
Michael Mazen Jafar, Chief Mktg. Officer
- Contact Info
Phone: (949) 284-4555
17901 Von Karman Ave.
Irvine, CA 92614
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.